Evidence map›Paper›PMID 29997499›Full record

ArticleFrontiers in pharmacology2018

Pantelis Natsiavas, Richard D Boyce, Marie-Christine Jaulent, Vassilis Koutkias

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pantelis NatsiavasCentre for Research & Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.
Richard D BoyceDepartment of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.
Marie-Christine JaulentInstitut National de la Santé et de la Recherche Médicale, U1142, LIMICS, Paris, France.
Vassilis KoutkiasCentre for Research & Technology Hellas, Institute of Applied Biosciences, Thessaloniki, Greece.

Funding

Addressing gaps in clinically useful evidence on drug-drug interactionsR01LM011838 · NLM · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BOYCE, RICHARD DAVID · 2014 to 2017
$1.6M
NLM NIH HHS R01 LM011838
6 · The paper itself

Abstract

Signal detection and management is a key activity in pharmacovigilance (PV). When a new PV signal is identified, the respective information is publicly communicated in the form of periodic newsletters or reports by organizations that monitor and investigate PV-related information (such as the World Health Organization and national PV centers). However, this type of communication does not allow for systematic access, discovery and explicit data interlinking and, therefore, does not facilitate automated data sharing and reuse. In this paper, we present

Indexed as

adverse drug reactionsdrug safetyFAIR principlesknowledge engineeringlinked dataontologiespharmacovigilance signalssemantic web

Identifiers

PMID29997499
PMCPMC6028717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.